Novel Combination Cancer Immunotherapy Summit 2024

Welcome to the Novel Combination Cancer Immunotherapy Summit - Supercharging Immunotherapies with Rational Combinations of ICIS, OVs, Adoptive Cells & Beyond The field of oncology is moving away from targeted monotherapies due to exhibited tumor resistance, low efficiency and off-target effects. Therefore, combination cancer immunotherapies are taking center stage as the next frontier in oncology but challenges remain before they can become the mainstream therapeutic strategy over the current standards of care. For the first time ever, immuno-oncology pioneers will unite at the Novel Combination Cancer Immunotherapy Summit 2024, to revolutionize cancer treatments through the rational selection and development of effective and durable combination therapies with checkpoint inhibitors, ADCs, adoptive cell therapies, oncolytic viruses and beyond. From overcoming resistance and relapse to improving patient selection, protocol design, regulatory adherence and route to market, join forces with leading experts in the field such as Merck, Pfizer and Amgen to advance your combination strategies. Stay ahead of the curve with scientific advancements that will unleash the true power of combination cancer immunotherapies by fast-tracking your pipelines towards commercially successful and therapeutically valuable assets.

Event Links

Website: https://go.evvnt.com/2511263-0

Tickets: https://go.evvnt.com/2511263-1

Brochure: https://go.evvnt.com/2511263-2

Read More

View Less